The Solidarity and Discovery trials now only focus on one drug, remdesivir.
The list of medication potential against Covid-19 continues to shrink: after hydroxychloroquine, the European clinical trials Solidarity and Discovery also abandoned the lopinavir / ritonavir treatment, considered ineffective and suspected of adverse effects.
After this decision, these two trials now only focus on a single drug, remdesivir, which has just obtained a conditional marketing within theEuropean Union.
L’association lopinavir / ritonavir already discontinued by Recovery
L’association both medication antivirals lopinavir and ritonavir, used for virus AIDS (and sold under the name of Kaletra), had already been abandoned in late June by another major clinical trial, the British Recovery.
The same decision was taken jointly on Saturday by the WHO (World Health Organization) for the Solidarity trial it is organizing and by French officials of a partner trial, Discovery.
WHO has at the same time definitively endorsed theabandon of hydroxychloroquine, decided on June 17.
” The results preliminary studies show that hydroxychloroquine andassociation lopinavir / ritonavir have little or no effect on reducing the mortality of patients hospitalized for Covid-19 compared to care standard, “said WHO in a statement.
Adverse effects on kidney function
In addition, the Discovery trial highlighted “the significantly higher frequency of serious adverse effects on kidney function” in patients taking lopinavir / ritonavir, said in a press release Inserm, a French research institute which organizes this essay. This is particularly the case “in patients hospitalized in intensive care,” adds Inserm.
According to the WHO and Inserm, all these results will be published in a scientific journal. Although dozens of treatments for Covid-19 have been evaluated around the world, none has yet shown remarkable efficacy, with the exception of a steroid, dexamethasone, in sick most affected. According to results of the Recovery trial, dexamethasone reduces mortality in sick the most seriously affected, those on artificial ventilation. For its part, remdesivir obtained a conditional marketing authorization within the EU on July 3, granted by the European Commission. An American study showed that this antiviral initially developed against Ebola hemorrhagic fever slightly reduced the recovery time of sick Covid-19 hospitalized (15 to 11 days on average). On the other hand, it has not proven any benefits in terms of reducing mortality.
Iceland bipBip & Source
–
